Literature DB >> 19424986

Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease.

Kelly Claire Simon1, Honglei Chen, Xiang Gao, Michael A Schwarzschild, Alberto Ascherio.   

Abstract

To determine if reproductive factors or exogenous estrogen are associated with risk of Parkinson's disease (PD), we conducted a prospective study with 22 years of follow-up among postmenopausal participants in the Nurses' Health Study. Relative risks (RRs) and 95% confidence intervals (CIs) of PD were estimated from a Cox proportional hazards model adjusting for potential confounders. Risk of PD was not significantly associated with any of the reproductive factors measured or exogenous estrogen use. Use of postmenopausal hormones, however, may modify the associations of smoking and caffeine intake with PD risk. The inverse relation between smoking and PD risk was attenuated among ever users of postmenopausal hormones (P for interaction = 0.05). Similar results were obtained for caffeine (P for interaction = 0.09). In exploratory analyses, women using progestin-only hormones were found to have an increased PD risk, but this result was based on a very small number of cases (n = 4). In this large longitudinal study, we found no evidence of a beneficial effect of exogenous or endogenous estrogens on risk of PD. The use of postmenopausal hormone use may interact with other risk factors, but findings are preliminary and need confirmation in other populations. 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424986      PMCID: PMC2751573          DOI: 10.1002/mds.22619

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  43 in total

1.  Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.

Authors:  S Callier; M Morissette; M Grandbois; D Pélaprat; T Di Paolo
Journal:  Synapse       Date:  2001-08       Impact factor: 2.562

2.  Compendium of physical activities: classification of energy costs of human physical activities.

Authors:  B E Ainsworth; W L Haskell; A S Leon; D R Jacobs; H J Montoye; J F Sallis; R S Paffenbarger
Journal:  Med Sci Sports Exerc       Date:  1993-01       Impact factor: 5.411

3.  Test of the National Death Index.

Authors:  M J Stampfer; W C Willett; F E Speizer; D C Dysert; R Lipnick; B Rosner; C H Hennekens
Journal:  Am J Epidemiol       Date:  1984-05       Impact factor: 4.897

4.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

Authors:  A Ascherio; S M Zhang; M A Hernán; I Kawachi; G A Colditz; F E Speizer; W C Willett
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

Review 5.  Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system.

Authors:  D E Dluzen
Journal:  J Neurocytol       Date:  2000 May-Jun

6.  Antiinflammatory effects of estrogen on microglial activation.

Authors:  A J Bruce-Keller; J L Keeling; J N Keller; F F Huang; S Camondola; M P Mattson
Journal:  Endocrinology       Date:  2000-10       Impact factor: 4.736

7.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Authors:  G A Colditz; S E Hankinson; D J Hunter; W C Willett; J E Manson; M J Stampfer; C Hennekens; B Rosner; F E Speizer
Journal:  N Engl J Med       Date:  1995-06-15       Impact factor: 91.245

8.  Reproducibility and validity of a semiquantitative food frequency questionnaire.

Authors:  W C Willett; L Sampson; M J Stampfer; B Rosner; C Bain; J Witschi; C H Hennekens; F E Speizer
Journal:  Am J Epidemiol       Date:  1985-07       Impact factor: 4.897

9.  Reproducibility and validity of self-reported menopausal status in a prospective cohort study.

Authors:  G A Colditz; M J Stampfer; W C Willett; W B Stason; B Rosner; C H Hennekens; F E Speizer
Journal:  Am J Epidemiol       Date:  1987-08       Impact factor: 4.897

10.  Relationships of age and reproductive characteristics with plasma estrogens and androgens in premenopausal women.

Authors:  J F Dorgan; M E Reichman; J T Judd; C Brown; C Longcope; A Schatzkin; W S Campbell; C Franz; L Kahle; P R Taylor
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995-06       Impact factor: 4.254

View more
  22 in total

1.  The complexities of hormonal influences and risk of Parkinson's disease.

Authors:  Connie Marras; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2014-04-30       Impact factor: 10.338

2.  Formulations of hormone therapy and risk of Parkinson's disease.

Authors:  Jessica I Lundin; Thanh G N Ton; Andrea Z LaCroix; W T Longstreth; Gary M Franklin; Phillip D Swanson; Terri Smith-Weller; Brad A Racette; Harvey Checkoway
Journal:  Mov Disord       Date:  2014-09-25       Impact factor: 10.338

3.  Associations between cancer and Parkinson's disease in U.S. elderly adults.

Authors:  D Michal Freedman; Jincao Wu; Honglei Chen; Eric A Engels; Lindsey R Enewold; Neal D Freedman; James J Goedert; Ralph W Kuncl; Mitchell H Gail; Ruth M Pfeiffer
Journal:  Int J Epidemiol       Date:  2016-03-17       Impact factor: 7.196

4.  Female reproductive factors, menopausal hormone use, and Parkinson's disease.

Authors:  Rui Liu; Donna Baird; Yikyung Park; Neal D Freedman; Xuemei Huang; Albert Hollenbeck; Aaron Blair; Honglei Chen
Journal:  Mov Disord       Date:  2013-12-18       Impact factor: 10.338

5.  Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Authors:  Hee Kyung Park; Sindana Ilango; Christina M Charriez; Harvey Checkoway; David Riley; David G Standaert; Yvette Bordelon; David R Shprecher; Stephen G Reich; Deborah Hall; Benzi Kluger; Connie Marras; Joseph Jankovic; Richard Dubinsky; Irene Litvan
Journal:  Mov Disord       Date:  2018-02-20       Impact factor: 10.338

6.  Caffeine intake, smoking, and risk of Parkinson disease in men and women.

Authors:  Rui Liu; Xuguang Guo; Yikyung Park; Xuemei Huang; Rashmi Sinha; Neal D Freedman; Albert R Hollenbeck; Aaron Blair; Honglei Chen
Journal:  Am J Epidemiol       Date:  2012-04-13       Impact factor: 4.897

Review 7.  The relevance of gender in Parkinson's disease: a review.

Authors:  Marina Picillo; Alessandra Nicoletti; Vincenza Fetoni; Barbara Garavaglia; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

8.  LRRK2 G2385R variant carriers of female Parkinson's disease are more susceptible to motor fluctuation.

Authors:  Chao Gao; Hao Pang; Xiao-Guang Luo; Yan Ren; Hong Shang; Zhi-Yi He
Journal:  J Neurol       Date:  2013-08-30       Impact factor: 4.849

9.  Risk of Parkinson's disease after tamoxifen treatment.

Authors:  Jeanne C Latourelle; Merete Dybdahl; Anita L Destefano; Richard H Myers; Timothy L Lash
Journal:  BMC Neurol       Date:  2010-04-12       Impact factor: 2.474

10.  Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan.

Authors:  Hsien-Feng Lin; Kuan-Fu Liao; Ching-Mei Chang; Cheng-Li Lin; Shih-Wei Lai
Journal:  Eur J Clin Pharmacol       Date:  2017-10-01       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.